Hà Lan - Tiếng Hà Lan - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

allergan pharmaceuticals international limited clonshaugh business & technology park d17 e400 dublin 17 (ierland) - deoxycholzuur 10 mg/ml - oplossing voor injectie - dinatriumwaterstoffosfaat 0-water (e 339) ; natriumchloride ; natriumhydroxide (e 524) ; water voor injectie ; zoutzuur (e 507), - deoxycholic acid

Hà Lan - Tiếng Hà Lan - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

allergan pharmaceuticals ireland castlebar road westport, county mayo (ierland) - carmellose natrium (e 466) 5 mg/ml - oogdruppels, oplossing - calciumchloride 2-water (e 509) ; kaliumchloride (e 508) ; magnesiumchloride 6-water (e 511) ; natriumchloride ; natriumhydroxide (e 524) ; natriumlactaat (r,s) (e 325) ; water, gezuiverd ; zoutzuur (e 507), calciumchloride 2-water (e 509) ; kaliumchloride ; magnesiumchloride 6-water (e 511) ; natriumchloride ; natriumhydroxide (e 524) ; natriumlactaat (r,s) ; water, gezuiverd ; zoutzuur (e 507), - artificial tears and other indifferent preparations

Hà Lan - Tiếng Hà Lan - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

allergan pharmaceuticals ireland castlebar road westport, co. mayo (ierland) - carmellose natrium (e 466) 10 mg/ml - oogdruppels, oplossing - calciumchloride 2-water (e 509) ; kaliumchloride (e 508) ; natriumchloride ; natriumlactaat (r,s) (e 325) ; water, gezuiverd, calciumchloride 2-water (e 509) ; kaliumchloride ; natriumchloride ; natriumlactaat (r,s) ; water, gezuiverd, - artificial tears and other indifferent preparations

Hà Lan - Tiếng Hà Lan - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

allergan pharmaceuticals ireland castlebar road westport, county mayo (ierland) - fluormetholon 1 mg/ml - oogdruppels, suspensie - benzalkoniumchloride ; dinatriumedetaat 2-water ; dinatriumwaterstoffosfaat 7-water (e 339) ; natriumchloride ; natriumdiwaterstoffosfaat 1-water (e 339) ; natriumhydroxide (e 524) ; polysorbaat 80 (e 433) ; polyvinylalcohol (e 1203) ; water, gezuiverd, benzalkoniumchloride ; dinatriumedetaat 2-water ; dinatriumwaterstoffosfaat 7-water (e 339) ; natriumchloride ; natriumdiwaterstoffosfaat 1-water (e 339) ; natriumhydroxide (e 524) ; polysorbaat 80 (e 433) ; polyvinylalcohol (e1203) ; water, gezuiverd, - fluorometholone

Hà Lan - Tiếng Hà Lan - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

novo nordisk b.v. flemingweg 8 2408 av alphen aan den rijn - glucagonhydrochloride 1,01 mg/flacon samenstelling overeenkomend met ; glucagon (rdna) 1 mg/flacon - poeder en oplosmiddel voor oplossing voor injectie - lactose 1-water ; natriumhydroxide (e 524) ; stikstof (head space) (e 941) ; water voor injectie ; zoutzuur (e 507), - glucagon

Hà Lan - Tiếng Hà Lan - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

novo nordisk b.v. flemingweg 18 2408 av alphen a/d rijn - estradiol 0,5-water samenstelling overeenkomend met ; ; estradiol ; norethisteronacetaat - filmomhulde tablet - glyceroltriacetaat (e 1518) ; hydroxypropylcellulose, laag gesubstitueerd (e 463) ; hypromellose (e 464) ; ijzeroxide rood (e 172) ; lactose 1-water ; magnesiumstearaat (e 470b) ; maÏszetmeel ; propyleenglycol (e 1520) ; talk (e 553 b) ; titaandioxide (e 171), - norethisterone and estrogen

Hà Lan - Tiếng Hà Lan - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

allergan pharmaceuticals ireland castlebar road westport, co. mayo (ierland) - prednisolonacetaat 10 mg/ml - oogdruppels, suspensie - benzalkoniumchloride ; boorzuur (e 284) ; dinatriumedetaat 2-water ; hypromellose (e 464) ; natriumchloride ; natriumhydroxide (e 524) ; polysorbaat 80 (e 433) ; trinatriumcitraat 2-water (e 331) ; water, gezuiverd ; zoutzuur (e 507), - prednisolone

Liên Minh Châu Âu - Tiếng Hà Lan - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - immunosuppressiva - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) is geïndiceerd voor de behandeling van volwassen patiënten met eerder behandelde multipel myeloom die niet in aanmerking komen voor transplantatie. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) is geïndiceerd voor de behandeling van volwassen patiënten met eerder behandelde multipel myeloom die niet in aanmerking komen voor transplantatie. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Liên Minh Châu Âu - Tiếng Hà Lan - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - immunosuppressiva - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) is geïndiceerd voor de behandeling van volwassen patiënten met eerder behandelde multipel myeloom die niet in aanmerking komen voor transplantatie. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 en 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) is geïndiceerd voor de behandeling van volwassen patiënten met eerder behandelde multipel myeloom die niet in aanmerking komen voor transplantatie. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 en 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Liên Minh Châu Âu - Tiếng Hà Lan - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - immunosuppressiva - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) is geïndiceerd voor de behandeling van volwassen patiënten met eerder behandelde multipel myeloom die niet in aanmerking komen voor transplantatie. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).